GLP-1 Agonists for MASLD and MASH UK 2026 Research Reference: SYNERGY-NASH, ESSENCE and Hepatic Endpoints

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

• 1. MASLD/MASH terminology and disease biology
• 2. Prevalence and epidemiology
• 3. Mechanistic rationale for GLP-1 in MASLD
• 4. ESSENCE — semaglutide in MASH (Phase 3)
• 5. SYNERGY-NASH — tirzepatide in MASH (Phase 2)
• 6. Retatrutide hepatic data (TRIUMPH-1 sub-study)
• 7. MASH endpoints: histology, MRI-PDFF, FibroScan
• 8. Liver biopsy considerations
• 9. MRI-PDFF as non-invasive endpoint
• 10. Elastography and FibroScan
• 11. Serum biomarkers: ELF, FAST, FIB-4, ALT
• 12. Comparison with THR-β agonists (resmetirom)
• 13. UK research protocol design for MASLD studies
• FAQ
• References

1. MASLD/MASH terminology and disease biology

The nomenclature for fatty liver disease was updated in 2023 by a multi-society consensus (AASLD, EASL, ALEH):

• MASLD (metabolic dysfunction-associated steatotic liver disease) replaces NAFLD (non-alcoholic fatty liver disease). Defined as hepatic steatosis (>5% by histology or imaging) plus at least one of five cardiometabolic risk factors: overweight/obesity, impaired fasting glucose/T2DM, hypertension, elevated triglycerides, or reduced HDL-C.
• MASH (metabolic dysfunction-associated steatohepatitis) replaces NASH. Defined as MASLD with histological evidence of steatosis, hepatocellular ballooning and lobular inflammation, with or without fibrosis.
• MetALD covers patients with MASLD who additionally consume alcohol above defined thresholds.

The disease spectrum progresses: MASLD → MASH → MASH with fibrosis (F2/F3) → MASH cirrhosis (F4) → hepatocellular carcinoma or hepatic decompensation. Fibrosis stage is the strongest predictor of liver-related mortality. Phase 3 trial endpoints focus on two parallel regulatory outcomes: (1) MASH resolution without worsening of fibrosis, and (2) fibrosis improvement (≥1 stage) without worsening of MASH.

2. Prevalence and epidemiology

MASLD global prevalence is approximately 32% of adults — the most common chronic liver disease worldwide. In UK adults with obesity, prevalence approaches 70-80%; in T2DM, 55-75%. MASH prevalence is approximately 5-7% of adults. Significant fibrosis (F2+) in the MASLD population is estimated at 6-7%, and cirrhosis at 1-2%.

The clinical relevance for GLP-1 research is that MASLD/MASH is highly co-prevalent with the obesity and T2DM populations already enrolled in large GLP-1 programmes. Most SURMOUNT and STEP participants had MASLD at baseline, enabling large hepatic sub-studies.

3. Mechanistic rationale for GLP-1 in MASLD

GLP-1 agonists affect hepatic steatosis through multiple mechanisms:

Indirect (weight-loss mediated): Weight loss itself is the most validated MASLD intervention; 7-10% weight loss resolves MASH in approximately 50% of patients. GLP-1-driven weight loss captures this entire effect.

Insulin sensitisation: GLP-1R-driven improvement in insulin sensitivity reduces hepatic de novo lipogenesis (normally stimulated by hyperinsulinaemia via SREBP-1c).

Direct hepatic receptor effects: Hepatic GLP-1R expression is low on hepatocytes but detectable on sinusoidal cells and hepatic stellate cells. The magnitude of direct hepatic GLP-1R effects is modest and debated, but may contribute to the observed liver-fat reduction beyond what weight loss alone would predict.

Hepatic inflammation: GLP-1R activation modulates Kupffer cell and hepatic macrophage inflammatory signalling, reducing TNF-α and IL-6 production in preclinical models.

Hepatic stellate cell effects: GLP-1R activation may reduce stellate cell activation and pro-fibrotic signalling, though clinical fibrosis improvement appears primarily weight-loss mediated.

4. ESSENCE — semaglutide in MASH (Phase 3)

ESSENCE (NCT04822181) is the first Phase 3 trial of a GLP-1 agonist with biopsy-confirmed MASH endpoints. It randomised 1,200 adults with MASH (F2 or F3 fibrosis) 2:1 to semaglutide 2.4 mg weekly or placebo, with liver biopsy at baseline, 72 weeks (primary) and 240 weeks (long-term fibrosis outcome). Results published 2025:

72-week primary endpoints:

• MASH resolution without worsening of fibrosis: semaglutide 62.9%, placebo 34.1% (p < 0.001)
• Fibrosis improvement (≥1 stage) without worsening of MASH: semaglutide 36.8%, placebo 22.4% (p < 0.001)
• Combined endpoint (both MASH resolution AND fibrosis improvement): semaglutide 32.7%, placebo 16.1%
• Body weight change: semaglutide −10.5%, placebo −2.0%
• ALT change: semaglutide −30%, placebo −10%

ESSENCE established semaglutide as the first GLP-1 agonist with a Phase 3 positive MASH endpoint. A long-term (240-week) outcomes read-out assessing progression to cirrhosis and hepatic decompensation is expected in 2028-2029.

5. SYNERGY-NASH — tirzepatide in MASH (Phase 2)

SYNERGY-NASH (NCT04166773) randomised 190 adults with biopsy-confirmed MASH (F2 or F3 fibrosis) to tirzepatide 5, 10 or 15 mg weekly or placebo, with biopsy at 52 weeks. Results published NEJM 2024:

52-week endpoints (MASH resolution without worsening of fibrosis):

• Placebo: 10%
• Tirzepatide 5 mg: 44%
• Tirzepatide 10 mg: 56%
• Tirzepatide 15 mg: 62%

Fibrosis improvement (≥1 stage) without worsening of MASH:

• Placebo: 30%
• Tirzepatide 5 mg: 55%
• Tirzepatide 10 mg: 51%
• Tirzepatide 15 mg: 51%

Notably, SYNERGY-NASH showed dose-responsive MASH resolution but not dose-responsive fibrosis improvement, suggesting the fibrosis response reaches a ceiling at doses producing sufficient weight loss.

A Phase 3 programme (SYNERGY-NASH 3, MAESTRO-NASH-type design) is in enrollment with expected primary read-out 2027.

6. Retatrutide hepatic data (TRIUMPH-1 sub-study)

The TRIUMPH-1 hepatic sub-study (Sanyal et al, Lancet Gastroenterol Hepatol 2024) randomised participants with MASLD (baseline liver fat ≥10% by MRI-PDFF) to retatrutide 1, 4, 8 or 12 mg weekly or placebo, with MRI-PDFF at 48 weeks:

• Placebo: liver fat change +0.3%
• Retatrutide 1 mg: −42.9%
• Retatrutide 4 mg: −57.0%
• Retatrutide 8 mg: −81.4%
• Retatrutide 12 mg: −82.4%
• Proportion achieving normal liver fat (<5%) at 12 mg: 85.7%

Retatrutide’s hepatic effect appears disproportionately large relative to its weight-loss effect, suggesting direct GLP-1/GIP/glucagon synergistic action on hepatic lipid metabolism. The glucagon component is mechanistically plausible: glucagon receptor activation increases hepatic fatty-acid oxidation and reduces de novo lipogenesis — effects that tirzepatide and semaglutide do not directly engage.

A dedicated Phase 3 MASH trial with retatrutide (TRIUMPH-NASH) is planned, expected to initiate 2025-2026.

7. MASH endpoints: histology, MRI-PDFF, FibroScan

Current regulatory gold standard (FDA, EMA) for MASH trials is paired liver biopsy at baseline and end of treatment, with independent blinded reading using the NASH CRN histological scoring system (NAS score components: steatosis, lobular inflammation, hepatocellular ballooning; plus fibrosis stage F0-F4).

Accepted regulatory endpoints for accelerated or conditional approval:

• MASH resolution without worsening of fibrosis
• Fibrosis improvement ≥1 stage without worsening of MASH
• (Combined above two is increasingly used as a primary endpoint)

For full approval, long-term clinical outcomes (hepatic decompensation, HCC, liver transplantation, all-cause mortality) are being collected in extended follow-up phases of ongoing trials.

8. Liver biopsy considerations

Research protocol design around liver biopsy requires careful consideration:

• Complication rate: ~1% for major bleeding; ~0.01% mortality
• Sampling variability: biopsy samples only ~1/50,000th of the liver, producing substantial inter-biopsy variability in fibrosis and inflammation scoring
• Central reading: essential for regulatory-quality trials; use of 2 or 3 independent blinded pathologists is standard
• Consent and screen-failure rate: roughly 30-40% of MASLD participants willing to enrol in a trial decline or screen-fail the biopsy step

9. MRI-PDFF as non-invasive endpoint

MRI proton density fat fraction (MRI-PDFF) is the preferred non-invasive steatosis endpoint for Phase 2 and mechanistic Phase 3 sub-studies:

• Precision: ±1-1.5% absolute liver fat fraction
• Correlation with histological steatosis: r = 0.85-0.90
• Threshold for MASLD diagnosis: ≥5% liver fat
• Response threshold: ≥30% relative reduction is considered a meaningful response
• Scan duration: ~15 minutes; no contrast required

MRI-PDFF is the workhorse early-phase endpoint and is the endpoint on which most of the cross-molecule comparative data (semaglutide, tirzepatide, retatrutide) has been generated.

10. Elastography and FibroScan

Vibration-controlled transient elastography (VCTE, FibroScan) and MR elastography (MRE) measure liver stiffness as a surrogate for fibrosis:

• FibroScan: widely available, low cost, modest reliability in obese participants (XL probe required above BMI ~32)
• MRE: superior reliability in obese cohorts; higher cost, less widely available
• FibroScan thresholds: F2 ≥ 8 kPa, F3 ≥ 10 kPa, F4 ≥ 14 kPa (approximate, etiology-dependent)

Elastography is the standard non-invasive fibrosis endpoint. Its precision is lower than histology, and it is typically used alongside serum fibrosis biomarkers rather than in isolation.

11. Serum biomarkers: ELF, FAST, FIB-4, ALT

• ALT: standard transaminase; drop of >17 IU/L or >20% from baseline at 24 weeks is associated with MASH improvement
• FIB-4: age + ALT + AST + platelet count formula; FIB-4 <1.3 rules out significant fibrosis
• ELF (Enhanced Liver Fibrosis): composite of hyaluronic acid, P3NP, TIMP-1; ELF ≥9.8 indicates significant fibrosis
• FAST (FibroScan-AST): composite of FibroScan liver stiffness + CAP + AST; ≥0.67 rules in at-risk MASH
• Pro-C3: emerging circulating collagen biomarker; early data suggests sensitivity to fibrosis change

12. Comparison with THR-β agonists (resmetirom)

Resmetirom (Rezdiffra, Madrigal Pharmaceuticals) is a liver-directed thyroid hormone receptor beta agonist, approved by the FDA in March 2024 as the first specifically-indicated MASH treatment. Its MAESTRO-NASH Phase 3 trial showed:

• MASH resolution without worsening of fibrosis: resmetirom 100 mg 29.9%, placebo 9.7%
• Fibrosis improvement ≥1 stage without worsening of MASH: resmetirom 100 mg 25.9%, placebo 14.2%
• Body weight change: modest (resmetirom is not a weight-loss drug)

Conceptual comparison with GLP-1 agonists:

• Resmetirom achieves MASH endpoints via hepatic THR-β-mediated mechanisms independent of weight loss
• GLP-1 agonists achieve MASH endpoints primarily via weight-loss-mediated mechanisms
• Combination therapy (resmetirom + GLP-1 agonist) is mechanistically rational and is under early investigation

For head-to-head comparison at 52-72 weeks, GLP-1 agonists (especially tirzepatide and semaglutide) produce larger MASH resolution rates than resmetirom in the available data, at the cost of the full GLP-1 class tolerability profile.

13. UK research protocol design for MASLD studies

A typical UK laboratory research protocol for MASLD/MASH investigation:

• Screening: FibroScan + CAP to identify at-risk MASH (FAST ≥0.35); MRI-PDFF to confirm liver fat ≥10%
• Primary inclusion: MASLD with F2-F3 fibrosis on baseline biopsy (if biopsy-confirmed protocol); or liver fat ≥10% on MRI-PDFF + elevated ELF (if non-invasive protocol)
• Intervention: semaglutide 2.4 mg weekly, tirzepatide titrated to 10 or 15 mg weekly, or retatrutide titrated to 8 or 12 mg weekly (dose and comparator depending on research question)
• Primary endpoint: MRI-PDFF at 24 or 48 weeks (for mechanistic studies) or liver biopsy at 52-72 weeks (for regulatory-quality studies)
• Secondary endpoints: FibroScan, ELF, FIB-4, ALT, body weight, HbA1c, lipid panel
• Safety endpoints: standard GLP-1 safety panel (amylase/lipase, ultrasound gallbladder, fundoscopy in T2DM cohort)

FAQ

Is liver biopsy still required for MASH trials?
For regulatory approval pathways, yes — FDA and EMA continue to require biopsy-based endpoints. For Phase 2 and mechanistic studies, MRI-PDFF alone is increasingly acceptable.

How much of the MASH effect is weight-loss-mediated?
Most but not all. Adjusted analyses suggest roughly 70-80% of the MASH resolution signal with GLP-1 agonists tracks weight loss; the remaining 20-30% is attributable to direct insulin-sensitisation and hepatic inflammation-modulating effects.

Does retatrutide’s glucagon-receptor agonism worsen or improve liver fat?
Improves. Glucagon receptor activation in hepatocytes increases fatty-acid oxidation and reduces de novo lipogenesis. The TRIUMPH-1 hepatic data suggest this is the mechanistic reason retatrutide produces disproportionately large liver-fat reductions.

Can GLP-1 agonists treat advanced MASH (F4 cirrhosis)?
Currently unclear. No pivotal trial has included cirrhotic patients. A semaglutide Phase 2 trial in compensated MASH cirrhosis (NCT03987451) showed no fibrosis improvement at 48 weeks despite weight loss, suggesting a “point of no return” beyond which fibrosis regression becomes refractory.

Are there combination trials?
Yes — resmetirom + semaglutide, and cilofexor (FXR agonist) + firsocostat (ACC inhibitor) + semaglutide combinations are in early-phase development.

What about HCC risk?
No adverse HCC signal has been reported with GLP-1 agonists; observational data suggest a modest protective effect, likely mediated by reduction in metabolic disease upstream of HCC. Definitive data awaits long-term outcome trials.

Which peptide is first-line for a UK MASLD research protocol?
Semaglutide for GLP-1R mechanistic studies; tirzepatide for dual-incretin MASLD studies with strongest weight-loss effect relative to approval status; retatrutide for triple-receptor studies emphasising direct hepatic lipid metabolism.

References

1. Sanyal AJ et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med 2025 (pre-publication; topline announced 2024).
2. Loomba R et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH). N Engl J Med 2024;391:299–310.
3. Sanyal AJ et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease (TRIUMPH-1 hepatic sub-study). Lancet Gastroenterol Hepatol 2024;9:795–806.
4. Newsome PN et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113–1124.
5. Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 2023;78:1966–1986.
6. Harrison SA et al. A phase 3 randomized, controlled trial of resmetirom in NASH with liver fibrosis (MAESTRO-NASH). N Engl J Med 2024;390:497–509.
7. Sanyal AJ, Brunt EM et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344–353 (historical reference; still broadly applicable).
8. European Association for the Study of the Liver (EASL). EASL-EASD-EASO Clinical Practice Guidelines on the management of MASLD. J Hepatol 2024;81:492–542.
9. Harrison SA et al. Clinical trial landscape in NASH. Clin Gastroenterol Hepatol 2023;21:2001–2014.
10. Jastreboff AM, Kaplan LM et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial (TRIUMPH-1 primary). N Engl J Med 2023;389:514–526.

UK Research Cluster Hubs

• GLP-1 Research Hub
• Tirzepatide Hub
• Retatrutide Hub
• BPC-157 Research Hub
• TB-500 Research Hub
• Growth-Hormone Peptides Hub
• Research-Grade Buyer’s Guide

Disclaimer: All peptides referenced are sold strictly for in vitro laboratory research use. Not for human consumption, veterinary use, food additive, cosmetic, or household purpose. Nothing in this article is medical advice. UK researchers are responsible for compliance with the Human Medicines Regulations 2012 and Misuse of Drugs Regulations 2001 where applicable.